In addition, our results are consistent with the change of Tim-3+PD-1+CD8+ T cells seen in mouse CRC models showing the appearance of Tim-3+PD-1+CD8+ T cells dominated the majority of CD8+ TILs only at a later tumor stage [30] and PD-1 and Tim-3 co-expression increased during AML progression [10]. The gene discussed is HAVCR2; the disease is neoplasm.